September 30, 2019 / 2:58 PM / 2 months ago

BRIEF-Roche: Tecentriq Reduced Risk Of Disease Worsening Compared With Chemotherapy Alone

Sept 30 (Reuters) - Roche Holding AG:

* IMVIGOR130 IS THE FIRST POSITIVE PHASE III STUDY OF A CANCER IMMUNOTHERAPY COMBINATION IN PEOPLE WITH PREVIOUSLY UNTREATED ADVANCED BLADDER CANCER

* TECENTRIQ COMBINATION REDUCED THE RISK OF DISEASE WORSENING OR DEATH (PROGRESSION-FREE SURVIVAL) COMPARED WITH CHEMOTHERAPY ALONE

* ENCOURAGING OVERALL SURVIVAL (OS) RESULTS WERE OBSERVED FOR TECENTRIQ PLUS CHEMOTHERAPY COMPARED WITH CHEMOTHERAPY ALONE IN THE INTENTION-TO-TREAT POPULATION (ITT), HOWEVER THESE DATA DID NOT REACH STATISTICAL SIGNIFICANCE AT THIS INTERIM ANALYSIS Source text: [bit.ly/2mijViQ] Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below